Paper15257707
The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint.
Boersma-Vreugdenhil GR and 8 others. Br J Haematol, 2004. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Papers, record 15257707. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15257707
- Cell line
- UM-3 [Human plasma cell myeloma]3 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Avian Proteins | Major topic |
| Chromosomes, Human, Pair 14 | Major topic |
| Chromosomes, Human, Pair 20 | Major topic |
| DNA-Binding Proteins | Major topic |
| Multiple Myeloma | Major topic |
| Oncogene Proteins | Major topic |
| Transcription Factors | Major topic |
| Translocation, Genetic | Major topic |
| Aged | |
| Blotting, Northern | |
| Cell Line, Tumor | |
| Female | |
| Gene Expression | |
| Humans | |
| In Situ Hybridization, Fluorescence | |
| MafB Transcription Factor | |
| Polymerase Chain Reaction | |
| Sequence Analysis, DNA |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40796955 | Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition. | Oncogene | 2025 | https://conductscience.org/library/papers/40796955 | PubMed |
| 40506426 | MAFB: a key regulator of myeloid commitment involved in hematological diseases. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40506426 | PubMed |
| 39160255 | Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. | Nat Genet | 2024 | https://conductscience.org/library/papers/39160255 | PubMed |
| 37692492 | Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression. | Genes Dis | 2024 | https://conductscience.org/library/papers/37692492 | PubMed |
| 36775962 | Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. | Cancer Med | 2023 | https://conductscience.org/library/papers/36775962 | PubMed |
| 36750911 | The role and regulation of Maf proteins in cancer. | Biomark Res | 2023 | https://conductscience.org/library/papers/36750911 | PubMed |
| 36071980 | A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors. | Explor Target Antitumor Ther | 2022 | https://conductscience.org/library/papers/36071980 | PubMed |
| 34885058 | Genome Instability in Multiple Myeloma: Facts and Factors. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34885058 | PubMed |
| 34215221 | Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34215221 | PubMed |
| 33357482 | Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. | Lancet Haematol | 2021 | https://conductscience.org/library/papers/33357482 | PubMed |
| 32050631 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32050631 | PubMed |
| 31582643 | Role of MafB in macrophages. | Exp Anim | 2020 | https://conductscience.org/library/papers/31582643 | PubMed |
| 29980194 | MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. | BMC Cancer | 2018 | https://conductscience.org/library/papers/29980194 | PubMed |
| 29686421 | The multiple myelomas - current concepts in cytogenetic classification and therapy. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29686421 | PubMed |
| 27829226 | SUMOylated MAFB promotes colorectal cancer tumorigenesis. | Oncotarget | 2016 | https://conductscience.org/library/papers/27829226 | PubMed |
| 26883334 | Risk Stratification in Multiple Myeloma. | Curr Hematol Malig Rep | 2016 | https://conductscience.org/library/papers/26883334 | PubMed |
| 24638926 | In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes. | Genes Chromosomes Cancer | 2014 | https://conductscience.org/library/papers/24638926 | PubMed |
| 24442204 | GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. | Blood Cancer J | 2014 | https://conductscience.org/library/papers/24442204 | PubMed |
| 22961061 | The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. | Blood Cancer J | 2012 | https://conductscience.org/library/papers/22961061 | PubMed |
| 18830254 | MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. | Leukemia | 2009 | https://conductscience.org/library/papers/18830254 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IGHD | 3495 | PubTator's text mining | https://conductscience.org/library/genes/3495 | NCBI Gene |
| MAFB | 9935 | PubTator's text mining | https://conductscience.org/library/genes/9935 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15257707
GET https://conductscience.org/api/papers/v1/15257707/cited_by?page=2